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Background. The safety of iron supplementation for young women is uncertain in malaria-endemic settings.
Methods. This was a double-blind, randomized controlled noninferiority trial in rural Burkina Faso.
Results. A total of 1959 nulliparae were assigned to weekly supplementation (60 mg iron and 2.8 mg folic acid) (n = 980) or 
2.8 mg folic acid (n = 979) until first antenatal visit (ANC1), or 18 months if remaining nonpregnant. Three hundred fifteen women 
attended ANC1, and 916 remained nonpregnant. There was no difference at ANC1 in parasitemia prevalence (iron, 53.4% [95% 
confidence interval {CI}, 45.7%–61.0%]; control, 55.3% [95% CI, 47.3%–62.9%]; prevalence ratio, 0.97 [95% CI, .79–1.18]; P = .82), 
anemia (adjusted effect, 0.96 [95% CI, .83–1.10]; P = .52), iron deficiency (adjusted risk ratio [aRR], 0.84 [95% CI, .46–1.54]; P = .58), 
or plasma iron biomarkers. Outcomes in nonpregnant women were parasitemia (iron, 42.9% [95% CI, 38.3%–47.5%]; control, 39.2% 
[95% CI, 34.9%–43.7%]; prevalence ratio, 1.09 [95% CI, .93–1.28]; P = .282); anemia (aRR, 0.90 [95% CI, .78–1.05]; P = .17), and iron 
deficiency (aRR, 0.99 [95% CI, .77–1.28]; P = .96), with no iron biomarker differences.
Conclusions. Weekly iron supplementation did not increase malaria risk, improve iron status, or reduce anemia in young, 
mostly adolescent menstruating women, nor in early pregnancy. World Health Organization Guidelines for universal supplementa-
tion for young nulliparous women may need reassessment.
Clinical Trials Registration. NCT01210040.
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Iron deficiency debilitates millions of young women in malar-
ia-endemic areas [1]. Iron supplementation is recommended 
where anemia is prevalent, but its safety and efficacy in malari-
ous areas is uncertain. Reviews of daily or intermittent iron sup-
plementation of nonpregnant women include few studies from 
malaria-endemic settings [2–4], and in iron supplementation 
trials in pregnancy, malaria outcomes are mostly not reported 
[5]. Two trials showed no increased malaria risk at delivery with 
daily antenatal iron supplementation, but malaria exposure was 
very low in one trial [6]. The other recruited mainly multi-
gravidae [7], although in sub-Saharan Africa the highest prev-
alence of Plasmodium falciparum malaria occurs during early 
pregnancy in primigravidae [8]. World Health Organization 
(WHO) guidelines on iron supplementation are applicable to 
both all-age pregnant women and all-age menstruating women. 
Safety of iron–folic acid supplementation in young nulliparous 
women before and during their first pregnancy in malaria-en-
demic areas has not been evaluated [9], and primigravidae are a 
higher malaria risk group than multigravidae.
As there had been no periconceptional trials of the safety and 
efficacy of iron supplementation in young nulliparous women 
living in malaria-endemic areas, we carried out a double-blind, 
randomized controlled noninferiority trial of malaria risk prior 
to and during early pregnancy in nulliparous women receiving 
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weekly iron and folic acid supplementation over a period of up 
to 18 months. The primary outcome was malaria parasitemia 
at first antenatal visit (ANC1). Secondary outcomes assessed 
malaria in women who remained nonpregnant, and supplement 
efficacy in reducing iron deficiency. Malaria endemicity in this 
study area is typical of many settings in sub-Saharan Africa with 
perennial malaria transmission.
METHODS
This periconceptional trial compared 2 cohorts supplemented 
with iron and folic acid vs folic acid alone: nonpregnant women 
and women who experienced pregnancy (additional details in 
Supplementary Data 1). The study received ethical approval in 
Burkina Faso (Comité d’Ethique pour la Recherche en Santé), 
the United Kingdom (Liverpool School of Tropical Medicine), 
and Belgium (University Hospital, Antwerp). All women in the 
trial provided written informed consent.
The study was conducted (April 2011–January 2014)  in the 
Nanoro Health and Demographic Surveillance System area 
(DHSS) where malaria is hyperendemic, with highest transmis-
sion between June and December [10]. The iron regimen used 
followed WHO guidelines updated in 2016 [3, 11] and satisfied 
recommended nutrient intakes for nonpregnant women assum-
ing 10%–25% iron absorption, with potential for good compli-
ance and reduced side effects compared to daily use.
Sample
Eligible participants were nulliparous, nonpregnant residents 
in 30 villages within the DHSS area. Potential participants 
aged 15–24  years identified through the DHSS database were 
approached by female field assistants (FFAs) for prescreening 
(additional details on informed consent procedures are shown 
in Supplementary Data 1). We excluded women with possible 
or confirmed pregnancy, chronic disease (eg, sickle cell), or ill-
ness requiring hospitalization. In this area, human immunode-
ficiency virus prevalence was 1.2% among women 15–49 years 
of age and 0.76% among pregnant women [12]. At enrollment 
demographic data, history of illness, obstetric history, last 
menstrual period, age at menarche, and sexual activity were 
recorded. A study clinician performed a general clinical exam-
ination, duplicate anthropometric measurements, and axillary 
temperature. We collected venous blood for plasma ferritin, 
serum transferrin receptor (sTfR), hepcidin, and C-reactive 
protein (CRP) measurements. Plasma was stored at –80°C (ad-
ditional laboratory details are shown in Supplementary Data 1). 
All participants received a long-lasting insecticidal net (LLIN) 
and single doses of albendazole (400 mg) and praziquantel.
Recruitment continued until the target number was reached. 
We anticipated 34% malaria prevalence in controls at ANC1 
[13]. Three hundred ninety women in the intervention and 
control groups would provide 90% power to detect a noninferi-
ority margin of 10% of malaria prevalence between trial arms. 
The number of nonpregnant nulliparous women aged 
15–24  years necessary to reach the required number of preg-
nant women was estimated from the proportion of nulliparous 
women (0.5) of childbearing age (0.23), aged 15–24 years (0.33), 
which provides 1973 potentially eligible women for a popula-
tion of 52 000 in the DHSS area (Figure 1).
Randomization and Blinding
Participants were individually randomized to receive weekly 
one of identical red colored vegetable cellulose (hypromellose) 
capsules (disintegration time <30 minutes; mean, 9.5 minutes), 
containing either ferrous gluconate (60  mg elemental iron, 
479  mg gluconate) and folic acid 2.8  mg, or folic acid alone. 
A  block allocation sequence was used with randomly deter-
mined block lengths. Four containers (4 ×  20 capsules) were 
assigned the same randomization code and were allocated to 
each participant. The FFA kept one container per participant, 
obtaining a replacement as required. Supplements were not 
kept by participants. Supplement codes, unknown to inves-
tigators and maintained independently by the sponsor, were 
revealed only after database lock and completion of data analy-
sis. Women received a card with a unique study number corre-
sponding to the randomization list. Supplements were stored at 
20°C–25°C and at ambient temperature while with FFAs.
Follow-up
FFAs provided supplements during weekly home visits and 
ingestion was directly observed. Participants not located for 2 
consecutive attempts but then recontacted, were reported as 
temporarily absent. In cases of fever (temperature ≥37.5°C) or 
history of fever in the previous 48 hours, the FFA performed 
a malaria Rapid Diagnostic Test (RDT; Bioline SD, Malaria 
Antigen P.f) and if positive, collected a blood sample for a thick 
film. RDT positives were treated with artesunate-amodiaquine 
following national guidelines. If no menses were reported at 5 
consecutive weekly visits, a urine pregnancy test was done for 
human chorionic gonadotropin, immediately or at the next 
weekly visit. Supplement safety and tolerability were evaluated 
by recording and grading adverse events (AEs). There were 2 
levels of recording: weekly FFA symptom using a checklist, and 
AEs through passive follow-up at health facilities. Serious AEs 
(SAEs), including deaths, were collected by active (weekly) and 
passive surveillance and reported according to available infor-
mation from FFAs and health center staff. SAE classification 
used all available clinical evidence and was not bound by strin-
gent laboratory or diagnostic criteria. If a woman died outside 
hospital, verbal autopsies were done by the DHSS team follow-
ing a standardized protocol.
At the end of the first malaria transmission season, fin-
ger-prick samples were taken from all nonpregnant participants 
for an interim safety analysis of malaria risk (microscopy and 
RDT). Positive RDTs were treated following national guidelines 
(additional details in procedures, Supplementary Data 1).
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Weekly supplements continued for 18 months, when women 
who remained nonpregnant were referred for end assessment. 
This included medical history, clinical examination, anthro-
pometry, and axillary temperature. A  venous blood sample 
was collected for malaria smear, hemoglobin (Hemocue AB), 
plasma ferritin, TfR, hepcidin, and CRP measurements, and for 
storage on filter paper. If febrile (temperature ≥37.5°C) or expe-
riencing fever in the previous 48 hours, an RDT was performed 
and women with positive results were treated. Urine pregnancy 
tests were repeated when indicated. On trial completion, ane-
mic nonpregnant women (hemoglobin [Hb] level  <12  g/dL) 
received iron and folic acid tablets daily for 1  month and, if 
severely anemic (Hb <8 g/dL), were referred to hospital.
Women becoming pregnant within the follow-up period 
were referred to Nanoro hospital for ANC1 with a study nurse/
doctor at 13–16 weeks’ gestation according to the last menstrual 
period. The weekly supplement was withdrawn and hematinics 
provided according to national policy (60 mg iron, 400 µg folic 
acid daily), although weekly follow-up continued. All women 
received the first dose of intermittent preventive treatment 
with sulfadoxine-pyrimethamine (IPTp-SP) if gestational age 
was >13 weeks. Women ≤13 weeks’ gestation, if RDT positive, 
were treated with oral quinine. At ANC1, procedures included 
routine antenatal care, venous blood collection for RDT, 
malaria film, hemoglobin, plasma ferritin, TfR, hepcidin, zinc 
protoporphyrin, and CRP measurements. Ultrasound was per-
formed to confirm pregnancy and to determine fetal location, 
number and viability, and gestational age. Following ANC1, 
women with moderate anemia (Hb 7.0–9.9  g/dL) received 
twice the recommended daily supplement during 1 month and, 
if severely anemic (Hb <7 g/dL), were referred to Nanoro hos-
pital. Women followed routine ANC visits where they received 
a second IPTp dose. Routine ANC and unscheduled health cen-
ter visits were recorded on study questionnaires by study cli-
nicians/nurses who collected data in health centers regularly 
(additional details in “Methods” in Supplementary Data 1). 
Procedures were similar at the second study visit (33–36 weeks’ 
gestation) when women were encouraged to deliver at Nanoro 
Hospital or the nearest health center, where free obstetric care 
was provided by the study. Study nurses examined babies for 
congenital malformations within 24–48 hours of delivery and 
information on infant survival was obtained by FFAs who vis-
ited or telephoned families.
Laboratory Measurements
Blood samples were transported to the laboratory within 3 
hours, centrifuged, and aliquoted. Blood films were Giemsa 
stained and read for malaria and parasite density (additional 
details on laboratory procedures are shown in Supplementary 
Data 1). Hemoglobin was measured (Sysmex automated 
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Figure 1. Trial profile. Stippled arrow indicates the number of women identified in early pregnancy at or within 2 months of the end assessment survey. Secondary outcome 
in nonpregnant women is malaria parasitemia. Abbreviations: ANC1, first antenatal visit; LTFU, lost to follow-up.
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analyzer) on fresh whole blood, and zinc protoporphyrin by 
fluorometry (Aviv Biomedical). Plasma ferritin and sTfR were 
measured using mean values from duplicate enzyme-linked 
immunosorbent assay (ELISA) samples (Spectro Ferritin S-22 
and TFC 94 TfR, RAMCO Inc). CRP was measured by ELISA 
(EU59131IBL, GmbH). Intra-assay coefficients of variation 
were all <10%. Plasma hepcidin was measured by competitive 
ELISA at an international reference laboratory (see laboratory 
procedures in Supplementary Data 1).
Outcomes
The primary outcome was Plasmodium parasitemia prevalence 
at ANC1. Prespecified secondary outcomes at ANC1 were prev-
alence of the following: RDT positivity with or without fever 
(temperature ≥37.5°C), clinical malaria (fever or history of fever 
in previous 48 hours with parasitemia), iron deficiency (defini-
tions in Supplementary Data 1), anemia, adverse pregnancy out-
comes (ie, miscarriage, stillbirth, perinatal or neonatal death), 
and congenital abnormality. In nonpregnant women at the end 
assessment, the proportion infected in the first year was assessed, 
along with the same prespecified outcomes as at ANC1. Adverse 
events captured incidence of prespecified gastrointestinal events 
(definitions and MedRA classification, grading and severity; 
see Supplementary Data 1 and 2 and Supplementary Table 3). 
Malaria parasitemia prevalence was measured in nonpregnant 
women during the first rainy season after at least 6 months of 
supplementation. Adherence to supplementation is reported.
Statistical Analysis
A statistical analysis plan was approved before database lock 
and release of the data and analyses follow that plan with only 
minor variation. Analyses followed CONSORT (Consolidated 
Standards of Reporting Trials) guidelines for noninferiority tri-
als [14]. Investigators were blinded to allocation (coded as A/B) 
until completion of the primary outcome analysis. Prevalence 
analyses based on data at specific time points utilized risk-ratio 
binomial models unadjusted and adjusted for season of trans-
mission (low or high), LLIN use (proportion of weekly visits 
with reported use prior to visit date), antimalarial use in 4 weeks 
prior to visit, and whether menarcheal at baseline. Parasite den-
sity and iron biomarkers were analyzed using analogous ordinary 
regression models following logarithmic transformation. Results 
are expressed as risk ratios (or density/biomarker level ratios) 
for iron treatment with 95% confidence interval (CI). Analyses 
of outcomes by iron deficiency utilized the same methodology, 
but with no menarche covariate. Mean hepcidin levels were 
compared between malaria parasitemia-positive and -negative 
women at ANC1 and the end assessment using Mann–Whitney 
U tests. Differences in proportions with elevated hepcidin were 
estimated using Fisher exact test and based on the 95th percen-
tile value for a healthy Dutch female population of comparable 
age [15]. Statistical significance was one-sided at α = .05.
Malaria incidence was calculated using Poisson regression 
models for the number of malaria episodes per woman with an 
offset of the logarithm of the period under observation (ie, until 
final assessment, ANC1, or loss to follow-up) with adjustment 
for LLIN use and menarche. Results are presented as incidence 
ratios for iron treatment with 95% CI. Time to first episode of 
malaria was analyzed using Cox regression models with partic-
ipants censored at ANC1, final assessment, or loss to follow-up 
with adjustment for season (baseline hazard stratified by en-
rollment month to allow for timing of rainy season), LLIN use, 
menarche, and iron deficiency at baseline (using adjusted fer-
ritin definition). Results are expressed as hazard ratios for iron 
treatment with 95% CI. All analyses were performed using R 
statistical environment version 3.3 [16].
RESULTS
Of 2317 women invited for screening, 1959 were randomly 
assigned weekly supplements (n  =  980, iron and folic acid; 
n = 979, folic acid); 1954 (99%) comprised the intention-to-treat 
population for the primary outcome. Four hundred five preg-
nancies (21%) occurred during follow-up, with another 73 (4%) 
early pregnancies identified at or shortly after the end assess-
ment survey (giving 478 pregnancies in total) (Figure 1). Median 
weekly supplement adherence at ANC1 was 79% (95% CI, 65%–
90%, iron) and 80% (95% CI, 59%–91%, folic acid) and at end 
assessment for nonpregnant women 83% (95% CI, 72%–91%, 
iron) and 84% (95% CI, 70%–92%, folic acid) (Supplementary 
Table 1 and Supplementary Data 2). Mean plasma ferritin and 
sTfR/log ferritin ratios were not improved in women with weekly 
adherence ≥80% (Figure 2). Median weekly LLIN use to ANC1 
was 48.8%, and to end assessment was 46.7%.
Baseline
Characteristics were similar between groups (Table 1). Adolescents 
(<20 years) comprised 93%. Women who remained nonpregnant 
were younger with lower body mass index. Women not attending 
were more illiterate and sexually active (Supplementary Table 2 
and Supplementary Data 2). Iron deficiency prevalence at base-
line did not differ in women lost to follow-up before ANC1 (9 
of 478 [2%]), or for nonpregnant women lost to follow-up be-
fore end assessment (501 of 1549 [32%]) compared to those fol-
lowed successfully. Iron deficiency prevalence was almost 2-fold 
higher using the sTfR/log ferritin ratio (22%) as biomarker than 
adjusted ferritin (12%) (Table 1). Elevated hepcidin concentra-
tion (>10.5 nmol/L) occurred in a quarter of women.
Prevalence of P.  falciparum parasitemia in nonpregnant 
women during the first rainy season was 36.4% (95% CI, 
33.7%–39.3%; n = 1167), with no difference by trial arm.
ANC1 Outcomes
Mean gestational age was 18.5 (standard deviation [SD], 
5.5) weeks (iron and folic acid) and 18.0 (SD, 6.0) weeks 
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(folic acid). Plasmodium parasitemia prevalence was 54.3%. 
This did not differ by trial arm (adjusted ratio, 1.0 [95% CI, 
.97–1.03]), nor when associated with fever. Incidence and time 
to the first symptomatic episode (fever plus parasitemia or RDT 
positivity) were not different between arms (Table 2).
There was no difference between study arms in anemia or iron 
deficiency prevalence, or mean concentrations of iron biomark-
ers (Table 3). Median hepcidin concentration was 3.9 nmol/L 
(interquartile range [IQR], 1.7–9.0) with, and 2.9 nmol/L (IQR, 
0.7–7.0) without, malaria parasitemia (P = .005). Elevated hep-
cidin was more frequent in parasitemic (22%) compared to 
nonparasitemic women (11%) (P = .015).
End Assessment Outcomes
Plasmodium parasitemia prevalence was 49.0% and did not dif-
fer by trial arm (adjusted ratio, 1.1 [95% CI, .95–1.28]), or if 
associated with fever. There was no difference between study 
arms in prevalence of anemia or iron deficiency, or mean con-
centrations of iron biomarkers (Table 3). Median hepcidin con-
centrations in women with and without malaria parasitemia 
were 3.4 (95%  CI  1.7–6.5) nmol/L and 2.9 (95%  CI  1.1–6.2) 
nmol/L, respectively (P = .011). Elevated hepcidin was similar 
in parasitemic (15%) compared with nonparasitemic women 
(16%) (P = .85).
Adverse Events
Supplements were well tolerated but with more frequent gas-
trointestinal events with iron supplementation (Relative Risk, 
1.29 [95% CI, .93–1.79]; P =  .12). Adverse events for all cate-
gories did not differ by trial arm (Supplementary Table 3 and 
Supplementary Data 2). We recorded 106 adult and 81 infant 
SAEs with almost equal frequency between groups (Table 4). Six 
adult deaths occurred (3 at delivery), unrelated to the interven-
tion or malaria. All congenital abnormalities (1.4%) occurred in 
controls. There were 17 infant/perinatal deaths, 12 to mothers 
who received iron.
DISCUSSION
We found that weekly iron and folic acid supplementation 
for up to 18 months did not affect significantly prevalence of 
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Figure 2. Mean ferritin concentration and serum transferrin receptor (sTfR)/log ferritin ratio in nonadherent and adherent women, by trial arm. Boxplots (median, interquartile 
range, and 90% range) for iron biomarkers in controls and iron-supplemented women at the 3 assessment points, subdivided by adherence to treatment. Adherence defined 
as receiving ≥80% weekly supplement intake up to first antenatal visit (ANC1), or end assessment in nonpregnant women. Broken reference lines are median baseline levels.
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Table 1. Baseline Characteristics of the Intention-to-Treat Dataset
Characteristic
All Iron
(n = 978)
All Control
(n = 976)
Nonpregnant Iron
(n = 766)
Nonpregnant 
Control
(n = 783)
Pregnant Iron
(n = 258)
Pregnant Control
(n = 220)
Sociodemographics
 Mean age, y (SD) 16.8 (1.7) 16.8 (1.8) 16.7 (1.7) 16.7 (1.8) 17.1 (1.7)  17.1 (1.7)
 Age <20 y 914/978 (93.5) 910/976 (93.2) 719/766 (93.9) 737/783 (94.1) 239/258 (92.6) 199/220 (90.5)
 Ethnicity Mossi 936/978 (95.7) 946/975 (97.0) 730/766 (95.3) 757/782 (96.8) 250/258 (96.9) 214/220 (97.3)
Missing 0/978 (0) 1/976 (0.1) 0/766 (0) 1/783 (0.1) 0/258 (0) 0/220 (0)
 Religion Catholic 414/978 (42.3) 405/975 (41.5) 317/766 (41.4) 327/782 (41.8) 118/258 (45.7) 86/219 (39.3)
Protestant 126/978 (12.9) 120/975 (12.3) 113/766 (14.8) 106/782 (13.6) 18/258 (7.0) 19/219 (8.7)
Muslim 251/978 (25.7) 250/975 (25.6) 187/766 (24.4) 203/782 (26) 75/258 (29.1) 52/219 (23.7)
Traditional 187/978 (19.1) 200/975 (20.5) 149/766 (19.4) 146/782 (18.7) 47/258 (18.2) 62/219 (28.3)
Missing 0/978 (0) 1/976 (0.1) 0/766 (0) 1/783 (0.1) 0/258 (0) 1/220 (0.5)
 Education None 595/975 (61.0) 578/974 (59.3) 447/763 (58.6) 450/781 (57.6) 176/257 (68.5) 142/220 (64.5)
Primary 212/975 (21.7) 201/974 (20.6) 168/763 (22.0) 169/781 (21.6) 54/257 (21) 38/220 (17.3)
Secondary 168/975 (17.2) 195/974 (20.0) 148/763 (19.4) 162/781 (20.7) 27/257 (10.5) 40/220 (18.2)
Missing 3/978 (0.3) 2/976 (0.2) 3/766 (0.4) 2/783 (0.3) 1/258 (0.4) 0/220 (0)
 Literacy Literate 329/966 (34.1) 347/966 (35.9) 278/756 (36.8) 297/774 (38.4) 68/255 (26.7) 62/218 (28.4)
Missing 12/978 (1.2) 10/976 (1.0) 10/766 (1.3) 9/783 (1.1) 3/258 (1.2) 2/220 (0.9)
 Occupationa Student 300/978 (30.7) 317/976 (32.5) 255/766 (33.3) 274/783 (35) 60/258 (23.3) 51/220 (23.2)
Trading 32/978 (3.3) 31/976 (3.2) 24/766 (3.1) 21/783 (2.7) 10/258 (3.9) 10/220 (4.5)
Domestic 534/978 (54.6) 515/976 (52.8) 401/766 (52.3) 407/783 (52) 154/258 (59.7) 120/220 (54.5)
Farmer 375/978 (38.3) 380/976 (38.9) 269/766 (35.1) 290/783 (37) 130/258 (50.4) 101/220 (45.9)
Other 5/978 (0.5) 4/976 (0.4) 3/766 (0.4) 2/783 (0.3) 3/258 (1.2) 3/220 (1.4)
Clinical characteristics
 Menarcheal 844/978 (86.3) 829/976 (84.9) 639/766 (83.4) 645/783 (82.4) 241/258 (93.4) 203/220 (92.3)
 Sexually active 249/978 (25.5) 241/975 (24.7) 159/766 (20.8) 164/782 (21.0) 98/258 (38) 82/220 (37.3)
 Height, cm (SD) 159.0 (6.0) 159.2 (6.0) 158.6 (6.0) 159.1 (6.1) 160.0 (5.7) 159.4 (5.6)
 Weight, kg (SD) 50.2 (6.8) 50.2 (7.2) 49.6 (6.9) 49.7 (7.2) 51.6 (6.0) 51.6 (6.7)
 BMI, kg/m2 (SD) 19.8 (2.1) 19.7 (2.2) 19.7 (2.1) 19.6 (2.2) 20.1 (1.8) 20.3 (2.1)
 BMI <18.5 kg/m2  257/978 (26.3) 277/976 (28.4) 222/766 (29.0) 246/783 (31.4) 46/258 (17.8) 39/220 (17.7)
 MUAC, cm (SD) 23.7 (2.1) 23.7 (2.2) 23.6 (2.1) 23.6 (2.2) 24.1 (1.8) 24.3 (2.2)
 Serum iron biomarkers
  Median CRP, mg/L (IQR) 0.59 (0.23–1.47) 0.51 (0.20–1.35) 0.58 (0.23–1.43) 0.50 (0.18–1.29) 0.72 (0.27–1.64)  0.70 (0.22–1.66)
   Missing 13/978 (1.3)  13/976 (1.3)  6/766 (0.8) 12/783 (1.5) 7/258 (2.7) 2/220 (0.9)
  CRP ≥10 mg/L 38/965 (3.9) 41/963 (4.3) 30/760 (3.9) 31/771 (4.0) 9/251 (3.6) 10/218 (4.6)
  Median ferritin, µg/L (IQR) 49.0 (28.0–78.0) 49.0 (26.0–82.0) 49.0 (28.0–79.8) 50.0 (27.0–81.0) 48.0 (28.0–74.5) 44.0 (26.0–81.0)
   Missing 12/978 (1.2) 14/976 (1.4) 8/766 (1.0) 12/783 (1.5) 4/258 (1.6) 3/220 (1.4)
  Median sTfR, mg/L (IQR)  6.32 (5.08–7.87) 6.28 (5.14–7.90) 6.32 (5.10–7.95) 6.26 (5.09–7.92) 6.20 (5.02–7.67) 6.34 (5.31–7.80)
   Missing  11/978 (1.1) 18/976 (1.8) 7/766 (0.9) 16/783 (2.0) 4/258 (1.6) 3/220 (1.4)
   Median sTfR/log10 ferritin 
ratio (IQR)
3.80 (2.88–5.13) 3.74 (2.88–5.36) 3.80 (2.88–5.13) 3.69 (2.86–5.25) 3.77 (2.88–5.13) 3.87 (2.94–5.61)
   Missing 14/978 (1.4) 18/976 (1.8) 9/766 (1.2) 16/783 (2.0) 5/258 (1.9) 3/220 (1.4)
   Median hepcidin, nmol/L 
(IQR)
4.80 (2.00–10.75) 4.30 (1.90–10.10) 4 .80 (1.90–10.75) 4.40 (1.90–10.00) 4.90 (2.32–10.67) 4.10 (1.80–10.70)
   Missing 11/978 (1.1) 16/976 (1.6) 7/766 (0.9) 14/783 (1.8) 4/258 (1.6) 3/220 (1.4)
   Elevated hepcidin 
>10.5 nM/Lb
251/967 (26.0) 222/960 (23.1) 196/759 (25.8) 172/769 (22.4) 65/254 (25.6) 55/217 (25.3)
    Missing  11/978 (1.1)  16/976 (1.6)  7/766 (0.9)  14/783 (1.8)  4/258 (1.6) 3/220 (1.4)
   Iron deficiencyc (adjusted 
ferritin)
105/962 (10.9) 125/961 (13) 84/758 (11.1) 100/770 (13) 25/250 (10)  26/217 (12)
   Missing 16/978 (1.6) 15/976 (1.5) 8/766 (1.0) 13/783 (1.7) 8/258 (3.1)  3/220 (1.4)
   Iron deficiencyd (sTfR/log 
ferritin ratio >5.6)
205/964 (21.3) 218/958 (22.8) 162/757 (21.4) 168/767 (21.9) 52/253 (20.6)  55/217 (25.3)
   Missing 14/978 (1.4) 18/976 (1.8) 9/766 (1.2) 16/783 (2.0) 5/258 (1.9)  3/220 (1.4)
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: BMI, body mass index; CRP, C-reactive protein; IQR, interquartile range; MUAC, mid-upper arm circumference; SD, standard deviation; sTfR, serum transferrin receptor.
aMultiple answers possible for subsistence activities (ie, trading, farming, and domestic work).
bHepcidin 95% range for women aged 18–24 years from reference Dutch population was median 2.6 nM; 2.5th percentile 0.7 nM; and 97.5th percentile 10.5 nM [15].
cFerritin <15 µg/L if CRP <10 mg/L or ferritin <70 µg/L if CRP ≥10 mg/L.
dRatio: sTfR (µg/L) to log10 ferritin (µg/L) >5.6.
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Plasmodium infection, iron deficiency, or anemia, compared 
with folic acid supplements alone in either the pregnant or 
nonpregnant cohort. Women receiving iron experienced non-
significantly increased gastrointestinal effects. Asymptomatic 
falciparum malaria infection was highly prevalent despite 
weekly active surveillance, access to free treatments, and treat-
ment of all RDT positives at the interim safety survey.
Our trial was double blind, tablet consumption was directly 
observed with balanced adherence covering wet and dry seasons, 
and active surveillance identified malaria episodes. Inadequate 
supplementation is unlikely as women absent for a number of 
weeks were tracked and resumed supplements, allowing them 
to reestablish their iron levels. Untreated chronic asymptomatic 
malaria may lead to tissue pathology within the gut [17] as well 
as elevated hepcidin concentrations [18], which would be ex-
pected to reduce iron absorption. In relation to a safety trial, an 
effect of iron supplementation on malaria risk becomes difficult 
to establish if there is limited iron absorption. Baseline preva-
lence of iron deficiency was comparable to estimates in a recent 
meta-analysis for low-income countries [19]. In the only in vivo 
iron absorption study to date in young women, conducted in 
Benin, markedly reduced iron absorption with asymptomatic 
malaria infection was demonstrated, and those participants had 
lower median parasite densities than we report at ANC1 [20]. 
Increasing iron dosage may be inadequate to overcome this lim-
itation. Because participant diets also influence iron absorption 
due to high phytate content or other micronutrient deficiencies, 
effects of iron supplements may also depend on food habits and 
bioavailability. Better malaria control for adolescents could po-
tentially both lower infection rates and improve food iron ab-
sorption, helping to meet growth requirements.
In 2016, WHO revised its guidelines on iron supplementation 
in menstruating women and adolescents girls, distinguishing 
settings where anemia prevalence is ≥40% from >20%. It rec-
ommended daily use (30–60 mg elemental iron) provided for 
3 consecutive months per year where prevalence is ≥40% [11], 
and weekly intermittent supplementation in 3 monthly annual 
cycles where anemia prevalence is 20%–40% [3]. Among non-
pregnant controls in our study, anemia prevalence was 45% at 
the end assessment but ≤20% were iron deficient. As we saw 
Table 2. Malaria at First Antenatal Visit and at End Assessment in Nonpregnant Nulliparae
Endpoint Iron Control Ratio P Value Adjusted Ratio
Adjusted  
P Valuea
Prevalence: ANC1
 No. 163 152
 RDT positive, No. (%) 95/161 (59.0) [51.3–66.3] 89/152 (58.6) [50.6–66.1] 1.01 [.84–1.21] 1.000 1.00 [.98–1.03] .718
 RDT positive and fever, No. (%) 15/163 (9.2) [5.7–14.6] 6/152 (3.9) [1.8–8.3] 2.33 [.93–5.85] .072 2.30 [.91–5.79] .075
 Microscopy positiveb, No. (%) 86/161 (53.4) [45.7–61.0] 84/152 (55.3) [47.3–62.9] 0.97 [.79–1.18] .820 1.00 [.97–1.03] .975
 Clinical malariac, No. (%) 9/161 (5.6) [3.0–10.3] 4/152 (2.6) [1.0–6.6] 2.12 [.67–6.75] .259 2.14 [.68–6.76] .194
 Parasite density, parasites/mm3, GM 2000 [1483–2696] 2244 [1674–3008] 0.89 [.59–1.35] 0.585 0.89 [.58–1.36] .584
Prevalence: end assessmenta
 No. 441 475
 RDT positive & fever, No. (%) 19/432 (4.4) [2.8–6.8] 30/464 (6.5) [4.6–9.1] 0.68 [.39–1.19] .188 0.69 [.39–1.21] .193
 Microscopy positiveb, No. (%) 189/441 (42.9) [38.3–47.5] 186/474 (39.2) [34.9–43.7] 1.09 [.93–1.28] .282 1.10 [.95–1.28] .180
 Clinical malariac, No. (%) 13/440 (3.0) [1.7–5.0] 22/474 (4.6) [3.1–6.9] 0.64 [.32–1.25] .228 0.67 [.34–1.31] .237
 Parasite density, parasites/mm3, GM 302 [248–368] 316 [259–386] 0.96 [.72–1.27] .754 0.96 [.73–1.27] .793
Incidence to end assessment in nonpregnantd
 Person-years of follow-up (No.) 1114.9 (936) 1121.1 (942)
 RDT positive (no./No.) 0.40 (445/1115) 0.40 (444/1121) 1.01 [.88–1.15] .908 1.01 [.89–1.15] .867
 RDT positive and fever (no./No.) 0.16 (174/1115) 0.17 (188/1121) 0.93 [.76–1.14] .494 0.94 [.76–1.15] .525
 Microscopy positive (no./No.) 0.25 (282/1115) 0.26 (286/1121) 0.99 [.84–1.17] .919 1.00 [.85–1.18] .971
 Clinical malariac (no./No.)  0.07 (79/1115) 0.08 (87/1121) 0.91 [.67–1.24] .558 0.92 [.68–1.25] .582
Proportion infected in first yeare
 No. at risk  978  976
 No. censored at 1 y (%)  294 (30.1) 294 (30.1)
 RDT positive and fever, %  13 [11–15] 14 [12–16]  0.89 [.72–1.11] .295  0.91 [.73–1.13] .386
 Clinical malariac, %  6 [5–8] 7 [5–8]  0.92 [.67–1.25] .588  0.92 [.68–1.26] .617
Values in square brackets indicate the 95% confidence interval.
Abbreviations: ANC1, first antenatal visit; GM, geometric mean; RDT, rapid diagnostic test.
aPrevalence adjusted for season at visit date, bed net use up to visit date, antimalarial use in month prior to visit, and menarcheal status at baseline. Ratio is risk ratio for iron treatment.
bParasite positive on blood smear.
cPlasmodium falciparum blood smear positive and fever ≥37.5°C.
dIncidence per person-year adjusted for weekly bed net adherence and menarcheal status at baseline; ratio is incidence ratio.
eCox regression model of time to first malaria episode, adjusted for baseline iron deficiency (ferritin), bed net use over observation time, visit, and menarcheal status at baseline, and strat-
ified by enrollment month; ratio is hazard ratio.
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no improved iron status at the higher dosage of 60  mg with 
up to 18 months of supplementation (maximum of 78 doses), 
it is questionable whether daily dosage, given over 3  months, 
would be more beneficial (maximum 90 doses). This population 
has low iron deficiency prevalence despite high anemia preva-
lence. Without evidence that iron supplementation is effective 
in young nulliparous women living in malaria-endemic areas, 
the basis for the WHO recommendation is weak and possibly 
unsafe in this group.
Adverse events were evenly balanced across trial arms, in-
cluding miscarriages, which could result from early pregnancy 
malaria. Gastrointestinal adverse events were nonsignificantly 
increased in iron-supplemented women. We have showed 
a 2-fold increased use of antibiotics for treatment of gastro-
intestinal infections in these women, with increased use of 
antifungals for lower genital infection in the nonpregnant 
iron-supplemented cohort [21]. Iron supplementation is re-
ported to increase diarrhea frequency in menstruating women 
from non-malaria-endemic areas [2].
Our study has some limitations. Nonattendance was greater 
than expected, with 25% of nonpregnant women not attending 
end assessment and 30% of pregnant women at ANC1, although 
contact with their families was retained to monitor AEs up to 
birth. Attrition was equivalent between trial arms. Domestic 
labor, early sexual activity, pregnancy before marriage, and mi-
gration outside the study area at marriage were contributory 
factors in failure to attend [22], and would be higher than in 
a nonadolescent population. Six percent of women were iden-
tified as nonmenarcheal at end assessment, possibly related to 
intentional misreporting to gain free treatment [23]. Bias due 
to different premenarcheal iron requirements would be unlikely 
as there were equal numbers across study arms, but premenar-
cheal status reduced the conception rate.
CONCLUSIONS
In a high-malaria-transmission area, weekly iron supplemen-
tation did not increase malaria risk, improve iron status, or re-
duce anemia in young, mostly adolescent menstruating women, 
nor in early pregnancy. Iron absorption studies are required to 
clarify whether chronic malaria influences iron uptake. Baseline 
characteristics were typical for adolescents in low-income, rural 
sub-Saharan Africa; thus, our results should apply to similar 
malaria-endemic areas with high rates of asymptomatic ado-
lescent malaria. Studies are warranted to improve malaria pre-
vention and control in adolescent populations and to shape 
relevant interfacing iron deficiency reduction strategies. Iron 
supplementation, as routinely given to populations such as this, 
is not helpful and is potentially harmful. WHO guidelines for 
universal supplementation in young nulliparous women may 
need to be reassessed.
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benefit the reader, the posted materials are not copyedited and 
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ments should be addressed to the corresponding author.
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Table 4. Serious Adverse Events
Adverse Event Iron Control
Adult SAE (n = 978) (n = 976)
 Accidental deatha 0 1
 Obstetric death 2 1
Other obstetric SAEb 12 7
 Severe malaria 27 20
 Other deathc 1 1
 Otherd 12 22
 Total SAE 54 52
Infant SAE (n = 231) (n = 206)
 Miscarriage 16 11
 Stillbirth 13 17
 Perinatal death* 6 0
 Neonatal death 4 3
 Infant death 1 1
 Death from congenital abnormalitye 0 1
 Other congenital abnormalitiesf, ** 0 5
 Other obstetric SAEb 2 0
 Other deathg 1 0
 Total SAE 43 38
Abbreviation: SAE, serious adverse event.
aOne death from drowning.
bSystems Order Classification = Pregnancy, puerperium and perinatal conditions, excluding 
deaths.
cNeoplasms: benign, malignant, and unspecified (liposarcoma and thoracic pain).
dSee Supplementary Data for summary of adverse events.
eSpina bifida.
fClub foot; congenital anomaly; polydactyly (all classified as unlikely or definitely not 
treatment related). Excludes abnormalities associated with stillbirth/miscarriage (one 
microcephaly).
gParalytic ileus.
*P = .021 (Fisher exact test).
**P = .011 for all abnormalities.
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